16 results about "Ovarian reserve" patented technology

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The application belongs to the technical field of biology and particularly relates to application of phosphatidylglycerol. The phosphatidylglycerol PG (20:4_22:6) is used as a biomarker, and through analysis on metabolites of follicular fluid, the application realizes diagnosis of decreased ovarian reserve (DOR) with high sensitivity, high specificity and high accuracy.

This invention discloses a liposome targeting ovarian mitochondria with mitochondrial optimization function, comprising a liposome body, PQQ, ovarian-specific targeting peptides YAGKLLISLSEERISAHHVP and TPP. PQQ is encapsulated within the liposome body, and the ovarian-specific targeting peptides YAGKLLISLSEERISAHHVP and TPP are respectively modified on the surface of the liposome body via amphiphilic polymer anchoring sites. This invention also discloses its preparation method and its application in the preparation of drugs for treating ovarian reserve insufficiency. The liposome of this invention significantly improves drug bioavailability, successfully overcomes the bottlenecks of existing delivery technologies, achieves highly efficient optimization of ovarian mitochondrial function, and provides a breakthrough solution for the precision treatment of diseases such as ovarian reserve insufficiency.

The invention discloses an exogenous FSH decreasing injection optimization method for inducing donor cattle superovulation, and relates to the technical field of animal husbandry biological breeding. The method comprises the following steps: acquiring physiological feature data and ovarian reserve function data of donor cattle, constructing an ovarian sensitivity evaluation model and calculating an ovarian sensitivity index; mapping the ovarian sensitivity index into an elimination rate constant, and generating an accumulated blood concentration sequence and a blood concentration metabolism curve according to a superposition principle by combining an injection time point sequence, an injection dosage sequence and a pharmacokinetic parameter table; a multi-target particle swarm optimization algorithm is adopted, follicular development synchronization rate maximization and ovarian over-stimulation risk minimization serve as targets, the fitness is calculated based on a blood concentration metabolism curve, iterative optimization is conducted, and the optimal initial injection dosage and the optimal decline gradient coefficient are output; generating an optimal decline dosing scheme parameter set according to the optimal decline dosing scheme parameter set; while the follicle development consistency and superovulation output are improved, the superovulation treatment stability is improved.

The invention relates to application of ergothioneine in preparation of a preparation for improving an ovarian reserve function. The invention creatively discovers that the ergothioneine has the function of improving the ovarian reserve function, and the obvious clinical value of the ergothioneine for people with the serum AMH level of 1.0-3.0 ng / mL in the key'window phase 'is defined for the first time. The ergothioneine not only can improve the serum AMH level and the sinus follicle count (AFC), but also can significantly reduce the abnormally increased FSH and LH levels. Meanwhile, aiming at bone loss caused by ovarian reserve function decline, the ergothioneine shows an excellent bone quality protection effect, the bone density can be improved, and the thickness and number of bone trabecula can be increased. In addition, the ergothioneine can improve climacteric symptoms, effectively maintain the nutritional state of target organs such as uterus, delay atrophy and regulate menstrual cycle disorder.

This invention discloses a compound moxa stick for warming yang and unblocking obstruction, its preparation method, and its application in improving reproductive system function. It belongs to the field of external preparations of traditional Chinese medicine. Addressing the problems of limited improvement effects of pure moxa sticks, lack of systematic design in compound moxa stick formulations, unclear synergistic effects between components, large fluctuations in conditioning effects, and difficulty in balancing conditioning effects and safety, this invention uses specific weight proportions of Artemisia argyi, Cyperus rotundus, Alpinia galanga, Cinnamomum cassia, Zingiber officinale, Illicium verum, Cinnamomum cassia twig, Spatholobus suberectus, Caesalpinia sappan, Smilax glabra, Euonymus fortunei, Citrus aurantium, Amomum villosum, Citrus reticulata peel, and Atractylodes lancea to prepare a compound moxa stick. The components synergistically enhance each other, and this product is used to prepare a moxibustion intervention product for improving the reproductive function of mammals. It can stably improve female ovarian reserve function and male asthenospermia, simultaneously regulate reproductive-related hormone levels, repair pathological damage to reproductive organs, and improve the quality of reproductive cells.

This invention discloses the application of N-acetyl-L-tryptophan, including the following applications: a. application in the preparation of drugs or health products that improve ovarian reserve function; b. application in the preparation of drugs or health products that improve or treat oocyte maturation disorders. This invention also discloses a drug comprising: N-acetyl-L-tryptophan or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, or an excipient; said drug can improve or treat oocyte maturation disorders and improve ovarian reserve function. This invention also discloses a health product comprising: N-acetyl-L-tryptophan or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, or an excipient; said health product can improve or treat oocyte maturation disorders and improve ovarian reserve function. This invention is the first to discover that N-acetyl-L-tryptophan has the efficacy of improving or treating oocyte maturation disorders and improving ovarian reserve function.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

The application discloses application of MSC-sEVs in treatment of reduced ovarian reserve. By targeting and activating DNA repair genes (such as PARP1) and combining NAD+ metabolism regulation, the ovarian function and reproductive potential of DOR are significantly improved. The method has high safety and unique advantages, and provides an innovative treatment scheme for patients with ovarian reserve dysfunction.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine preparation for improving female ovarian functions and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 0.4-0.6 part of a traditional Chinese medicine active agent, 0.8-1.6 parts of Glu-chitosan and 1-2 parts of sodium alginate. Wherein the traditional Chinese medicine active agent is prepared by extracting specific traditional Chinese medicines such as dogwood, Chinese yam, amomum villosum and angelica sinensis and then inoculating activated lactobacillus plantarum for fermentation, so that the bioavailability can be effectively improved, and the curative effect can be improved. The Glu-chitosan is prepared by grafting reaction of chitosan and glucose. The traditional Chinese medicine active agent is embedded by adopting Glu-chitosan and sodium alginate, so that the slow-release effect and the bioavailability are effectively improved. The prepared traditional Chinese medicine preparation can effectively solve the problem that the ovarian reserve function is reduced.

The invention discloses a construction method and application of a fetal ovarian reserve function reduction animal model based on an HDAC1 / USP9X pathway. According to the fetal-derived ovarian reserve function reduction model, 20 mg / kg of aspirin is given to rodents (such as Kunming mice) through intragastric administration in 9-18 days of pregnancy, and typical ovarian reserve function reduction occurs after female offspring birth. Based on an in-vitro cultured fetal ovarian model, the disintegration of germ cell nests and the assembly of primordial follicles can be improved by treating with an HDAC1 specific inhibitor Pyroxamide, and the injury caused by aspirin can be reversed. Therefore, the animal model established by the invention is novel, reliable, simple and convenient, meanwhile, the Pyroxamide has the effect of improving the reduction of the ovarian reserve function, and a new way is provided for preventing and treating the reduction of the fetal ovarian reserve function.

The present application relates to the technical field of pregnancy rate prediction, and particularly relates to a model establishment method and system for predicting pregnancy rate of early-onset ovarian dysfunction, which obtains clinical data of a patient, identifies four types of prediction key points, including basic physiological characteristics, ovarian reserve function, treatment intervention and pregnancy outcome correlation. When the total amount of key points exceeds a first threshold value, a dimensionality reduction improved feedforward neural network is constructed, and basic physiological characteristics and treatment intervention data are used as inputs to predict ovarian function and pregnancy outcome. When the number of key points is small, a graph neural network is used, a directed graph structure is constructed based on clustering and hierarchical relationship of each key point, and node state is dynamically updated based on basic physiological characteristics, so as to realize classification prediction of ovarian function and pregnancy risk, improve prediction accuracy and model interpretability, and provide personalized and intelligent decision support for fertility evaluation of POI patients.

The invention discloses an application of a Polygala fallax Hemsl aqueous extract in preparation of a medicine for treating hypoovarian reserve (DOR), and belongs to the technical field of traditional Chinese medicine Yao medicine. It is found for the first time that the polygala aureocauda aqueous extract can significantly improve the orbital cycle disorder of DOR mice, significantly increase the AMH and E2 levels of the DOR mice, significantly reduce the FSH and LH levels, significantly reduce the atresia follicle rate of the DOR mice and significantly increase the maturation rate of oocytes; therefore, the polygala fallax water extract can be used for treating ovarian reserve function decline and preventing and treating ovarian function impairment caused by chemotherapeutic drugs.

This application relates to the field of pharmaceutical technology, and more particularly to a traditional Chinese medicine composition and its application in prolonging the lifespan of the body and ovaries, preventing ovarian dysfunction, protecting ovarian reserve, and improving menopausal-related diseases. The pharmaceutical composition includes Rehmannia glutinosa (processed), Gynostemma pentaphyllum, Angelica sinensis, Lycium barbarum, Poria cocos, Ligustrum lucidum, Astragalus membranaceus, Paeonia lactiflora, Bupleurum chinense, Salvia miltiorrhiza, Curcuma longa, Albizia julibrissin, Cuscuta chinensis, Ziziphus jujuba var. spinosa, and Triticum aestivum. This application discovers a traditional Chinese medicine composition that can effectively prolong the lifespan of the body and ovaries, prevent ovarian dysfunction, protect ovarian reserve, and improve menopausal-related diseases. Specifically, by combining the above-mentioned herbs, it is possible to effectively prolong the lifespan of the body and ovaries, improve ovarian function, and alleviate menopausal-related diseases. The traditional Chinese medicine composition provided in this application has significant implications in the fields of aging and ovarian function protection.

The invention discloses a traditional Chinese medicine Yao medicine for improving an ovarian reserve function and application thereof, and belongs to the technical field of traditional Chinese medicine Yao medicines. It is found for the first time that the Ziyuan aqueous extract can significantly improve the orbital cycle disorder of DOR mice, significantly increase the AMH and E2 levels of the DOR mice, significantly reduce the FSH and LH levels, significantly reduce the atresia follicle rate of the DOR mice and significantly increase the maturation rate of oocytes; therefore, the Ziyuan water extract can be used for treating ovarian reserve function decline and preventing and treating ovarian function impairment caused by chemotherapeutic drugs.

The invention provides a spermatogenic function multi-dimensional evaluation method and system, and the method comprises the steps: obtaining abnormal parameters from spermatogenic problem positioning, determining the deviation degree through comparison with a preset normal range, and obtaining a male evaluation score; if the type is female, extracting an ovarian reserve mark from the preliminary classification result, processing reserve parameters by adopting a support vector machine model, judging a reserve level, and obtaining reserve problem positioning; obtaining a level index from reserve problem positioning, determining a reserve deviation by calculating a difference with a preset reference, and obtaining a female evaluation score; integrating the deviation data from the male assessment score or the female assessment score, generating a comprehensive feedback report by adopting a fusion algorithm, and determining an overall fertility level; and grade information is extracted from the comprehensive feedback report, a clinical result is generated through a rapid output module, and a final evaluation conclusion is obtained.